aluates Reports

$ 0.0

Automative

Global Duchenne Muscular Dystrophy Market Research Report 2026

Published Date: 2026-03-04

Report Code: QYRE-Auto-12K736

Global Duchenne Muscular Dystrophy Market Size Manufacturers Supply Chain Sales Channel and Clients 2021 2027

BUY CHAPTERS

Global Duchenne Muscular Dystrophy Market Research Report 2026

Code: QYRE-Auto-12K736

Report

2026-03-04

Pages:103

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

PTC Therapeutics

Sarepta Therapeutics

Pfizer Inc

Bristol–Myers Squibb

Italfarmaco S.p.A.

Santhera Pharmaceuticals

Duchenne Muscular Dystrophy Market Size

The global Duchenne Muscular Dystrophy market was valued at US$ 2126 million in 2025 and is anticipated to reach US$ 4974 million by 2032, at a CAGR of 13.1% from 2026 to 2032.

Duchenne Muscular Dystrophy Market

Duchenne Muscular Dystrophy is an x-linked genetic disorder that affects mostly boys. In Duchenne, boys begin to show signs of muscle weakness as early as two to five years of age. The disease gradually weakens the skeletal or voluntary muscles in the arms, legs and trunk. Due to progressive muscle weakness, Duchenne patients are often wheelchair bound between the ages of seven and 13 years old. At a later stage, the boys' respiratory and cardiac muscles are also affected and for most boys, respiratory and cardiac failure are major causes of death, often prevalent by the age of 20.

Global Duchenne Muscular Dystrophy key players include Sarepta Therapeutics, PTC Therapeutics, etc. North America is the largest market, with a share over 70%, followed by Europe, and Japan, both have a share over 25 percent. In terms of product, Exondys 51 is the largest segment, with a share over 55%. And in terms of application, the largest application is Hospitals, followed by Clinics, Home Care, etc.

The Duchenne muscular dystrophy (DMD) market is primarily driven by the following factors:

1. Disease Burden and Epidemiological Data

1.1 Incidence and Patient Population

Global Data: DMD is a rare, X-linked genetic disease with a global incidence of approximately 6 cases per 100,000 people, with the majority of patients being male (due to recessive inheritance of the X chromosome, females require two defective copies to develop the disease).

China Data: The incidence of DMD in China is approximately 1 in 3,853, with approximately 60,000 to 70,000 patients nationwide. The majority of patients are children and adolescents, with the peak incidence occurring between the ages of 3 and 5 years.

Regional Distribution: Europe (Sweden and Norway), North America (the United States and Canada), and China are the most prevalent regions, with the Asia-Pacific region (such as Australia and Japan) contributing approximately 30% of clinical trials.

1.2 Disease Characteristics and Impact

Symptoms and Prognosis: Patients typically experience delayed motor development (e.g., difficulty sitting and walking) at 2-3 years of age, lose the ability to walk around 12 years of age, and ultimately die from respiratory or cardiopulmonary failure. The average life expectancy is approximately 40 years. Complications: Approximately 30% of patients experience mild intellectual disability, and skeletal deformities (such as scoliosis) and muscle atrophy significantly impact their quality of life.

2. Treatment Advances and Drugs in Development

2.1 Marketed Drugs

Corticosteroids: Corticosteroids such as deflazacort (Emflaza) and vamorolone are traditional treatments that slow disease progression through their anti-inflammatory effects, but they can also cause side effects (such as weight gain and growth suppression).

Exon-skipping therapy: Antisense oligonucleotides (ASOs) are used to skip the mutated exon, restoring some dystrophin function. Approved drugs include:

Exondys 51 (exon 51 skipping, affecting 13% of DMD patients), Vyondys 53 (exon 53 skipping, affecting 8%), and Amondys 45 (exon 45 skipping).

Viltepsiso (exon 53 skipping, manufactured by Nippon Shinyaku Co., Ltd.). Gene Therapy: Elevidys (SRP-9001) is the first approved gene therapy for DMD. It delivers the dystrophin gene via an AAV vector. Its indication will be expanded to patients aged 4 years and older (regardless of ambulatory status) in 2024.

2.2 Drugs and Technologies in Development

Gene Therapy: Several companies (such as Sarepta Therapeutics and Roche) are advancing gene therapies to address the underlying genetic defect.

Cell Therapy and Gene Editing: Gene editing tools such as CRISPR technology have shown promise in preclinical studies but have yet to enter large-scale application.

HDAC inhibitors: For example, givinostat (Duvyzat) inhibits histone deacetylases to slow muscle degeneration and was approved by the FDA in 2024 for patients aged 6 years and older.

3. Policy Support and Orphan Drug Designation

3.1 Global Policy Differences

US: The FDA has approved several DMD drugs (such as Exondys 51 and Elevidys) through accelerated approval, but requires confirmatory trials to verify efficacy. The European Union (EU) has refused to renew approval for some drugs (such as Exondys 51), while the UK's MHRA has retained access to some drugs, reflecting regional policy differences.

China has included DMD in its first list of rare diseases, providing dedicated funding to support research and development, and promoting priority review and reimbursement of new drugs (such as valmorolone).

3.2 Orphan Drug Incentives

Tax Incentives and Expedited Approval: Most countries use orphan drug designation (such as the US Orphan Drug Act) to provide tax breaks, research and development subsidies, and fast-track approvals, reducing R&D risks for companies.

Safety Net Programs: Some countries (such as France and Germany) waive economic analysis for drugs with minimal budgetary impact, accelerating patient access.

4. Patient Needs and Organizational Activities

4.1 Patient Demands and Quality of Life

Evolving Treatment Needs: Patients and families have a strong demand for treatments that reduce the side effects of traditional hormones (such as newer dissociative steroids like valmorolone), driving the development of innovative therapies. Raising Disease Awareness: Patient organizations (such as the Duchenne Muscular Dystrophy Association) are raising public awareness of DMD through advocacy, advocating for more treatment options and medical insurance coverage.

4.2 Optimizing Clinical Management

Multidisciplinary Integrated Management: For example, Beijing Children's Hospital has established a multidisciplinary DMD team (including neurology, rehabilitation, and cardiology) to provide personalized treatment throughout the lifespan.

Early Diagnosis and Intervention: Motor function assessments, muscle enzyme profiles (creatine kinase elevation of 20-200 times), and genetic testing are used to achieve early diagnosis and optimize the therapeutic window.

5. Capital Investment and R&D Trends

5.1 Pharmaceutical Company Strategies

International giants: Sarepta Therapeutics (leading in exon skipping therapies), Roche (gene therapy collaborations), Italfarmaco (HDAC inhibitors), and other companies are driving the development of innovative therapies.

Chinese companies: Shufang Pharmaceuticals (valmorolone launched domestically), New Sprout Gene, and Jinweike are investing in gene therapy, bringing new drugs to market through collaborative acquisitions or independent R&D. 5.2 Venture Capital and M&A

Capital Activity: In 2023-2024, several international pharmaceutical companies entered into collaborations with Chinese DMD R&D companies (e.g., Cranbury Pharmaceuticals introduced generic versions of deflazacort), promoting the development of innovative therapies such as gene therapy.

Market Forecast: China's DMD drug market is expected to continue to grow from 2024 to 2030, with innovative therapies (e.g., gene therapy) dominating the market and driving increased market penetration.

6. Technological Advances and Future Directions

6.1 Gene Therapy Breakthroughs

Elevidys' Milestone: As the first DMD gene therapy, Elevidys addresses the underlying genetic cause with a one-time treatment. Despite challenges with immunity and contraindications, it represents a future direction.

Long-Term Efficacy Verification: Confirmatory trials (e.g., the EMBARK trial) will continuously track patient functional improvements (e.g., North Star Walk Assessment, Time to Stand), verifying the durability of gene therapy.

6.2 Personalized Treatment and Digitalization

Precision Medicine: Developing personalized treatment plans based on the patient's genetic mutation type (e.g., exon skipping therapy) improves efficacy. Digital healthcare applications: Technologies such as online diagnosis and treatment, remote monitoring (such as the "Green Channel" system at Beijing Children's Hospital) optimize patient management and enhance the medical experience.

The growth of the Duchenne muscular dystrophy (DMD) market is primarily driven by the disease burden, treatment advances (particularly gene therapy), policy support, escalating patient needs, and capital investment. In the future, with the approval of more innovative therapies and expanded medical insurance coverage, market demand will be further unleashed, and cutting-edge technologies such as gene therapy are expected to become mainstream treatments.

This report delivers a comprehensive overview of the global Duchenne Muscular Dystrophy market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Duchenne Muscular Dystrophy. The Duchenne Muscular Dystrophy market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Duchenne Muscular Dystrophy market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Duchenne Muscular Dystrophy manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Duchenne Muscular Dystrophy Market Report

Report Metric	Details
Report Name	Duchenne Muscular Dystrophy Market
Accounted market size in 2025	US$ 2126 million
Forecasted market size in 2032	US$ 4974 million
CAGR	13.1%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Exondys 51 Emflaza Translarna
Segment by Application	Hospitals Clinics Home Care
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Duchenne Muscular Dystrophy companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Duchenne Muscular Dystrophy Market growing?

Ans: The Duchenne Muscular Dystrophy Market witnessing a CAGR of 13.1% during the forecast period 2026-2032.

What is the Duchenne Muscular Dystrophy Market size in 2032?

Ans: The Duchenne Muscular Dystrophy Market size in 2032 will be US$ 4974 million.

What is the Duchenne Muscular Dystrophy Market share by type?

Ans: In terms of product, Exondys 51 is the largest segment, with a share over 55%.

Who are the main players in the Duchenne Muscular Dystrophy Market report?

Ans: The main players in the Duchenne Muscular Dystrophy Market are Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco, Santhera Pharmaceuticals

What are the Application segmentation covered in the Duchenne Muscular Dystrophy Market report?

Ans: The Applications covered in the Duchenne Muscular Dystrophy Market report are Hospitals, Clinics, Home Care

What are the Type segmentation covered in the Duchenne Muscular Dystrophy Market report?

Ans: The Types covered in the Duchenne Muscular Dystrophy Market report are Exondys 51, Emflaza, Translarna

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type: 2021 vs 2025 vs 2032

1.2.2 Exondys 51

1.2.3 Emflaza

1.2.4 Translarna

1.3 Market by Application

1.3.1 Global Duchenne Muscular Dystrophy Market Growth by Application: 2021 vs 2025 vs 2032

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Home Care

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Duchenne Muscular Dystrophy Market Perspective (2021–2032)

2.2 Global Duchenne Muscular Dystrophy Growth Trends by Region

2.2.1 Global Duchenne Muscular Dystrophy Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Duchenne Muscular Dystrophy Historic Market Size by Region (2021–2026)

2.2.3 Duchenne Muscular Dystrophy Forecasted Market Size by Region (2027–2032)

2.3 Duchenne Muscular Dystrophy Market Dynamics

2.3.1 Duchenne Muscular Dystrophy Industry Trends

2.3.2 Duchenne Muscular Dystrophy Market Drivers

2.3.3 Duchenne Muscular Dystrophy Market Challenges

2.3.4 Duchenne Muscular Dystrophy Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Duchenne Muscular Dystrophy Players by Revenue

3.1.1 Global Top Duchenne Muscular Dystrophy Players by Revenue (2021–2026)

3.1.2 Global Duchenne Muscular Dystrophy Revenue Market Share by Players (2021–2026)

3.2 Global Top Duchenne Muscular Dystrophy Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Duchenne Muscular Dystrophy Revenue

3.4 Global Duchenne Muscular Dystrophy Market Concentration Ratio

3.4.1 Global Duchenne Muscular Dystrophy Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Duchenne Muscular Dystrophy Revenue in 2025

3.5 Global Key Players of Duchenne Muscular Dystrophy Head Offices and Areas Served

3.6 Global Key Players of Duchenne Muscular Dystrophy, Products and Applications

3.7 Global Key Players of Duchenne Muscular Dystrophy, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Duchenne Muscular Dystrophy Breakdown Data by Type

4.1 Global Duchenne Muscular Dystrophy Historic Market Size by Type (2021–2026)

4.2 Global Duchenne Muscular Dystrophy Forecasted Market Size by Type (2027–2032)

5 Duchenne Muscular Dystrophy Breakdown Data by Application

5.1 Global Duchenne Muscular Dystrophy Historic Market Size by Application (2021–2026)

5.2 Global Duchenne Muscular Dystrophy Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Duchenne Muscular Dystrophy Market Size (2021–2032)

6.2 North America Duchenne Muscular Dystrophy Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Duchenne Muscular Dystrophy Market Size by Country (2021–2026)

6.4 North America Duchenne Muscular Dystrophy Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Duchenne Muscular Dystrophy Market Size (2021–2032)

7.2 Europe Duchenne Muscular Dystrophy Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Duchenne Muscular Dystrophy Market Size by Country (2021–2026)

7.4 Europe Duchenne Muscular Dystrophy Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Duchenne Muscular Dystrophy Market Size (2021–2032)

8.2 Asia-Pacific Duchenne Muscular Dystrophy Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Duchenne Muscular Dystrophy Market Size by Region (2021–2026)

8.4 Asia-Pacific Duchenne Muscular Dystrophy Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Duchenne Muscular Dystrophy Market Size (2021–2032)

9.2 Latin America Duchenne Muscular Dystrophy Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Duchenne Muscular Dystrophy Market Size by Country (2021–2026)

9.4 Latin America Duchenne Muscular Dystrophy Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Duchenne Muscular Dystrophy Market Size (2021–2032)

10.2 Middle East & Africa Duchenne Muscular Dystrophy Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Duchenne Muscular Dystrophy Market Size by Country (2021–2026)

10.4 Middle East & Africa Duchenne Muscular Dystrophy Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Sarepta Therapeutics

11.1.1 Sarepta Therapeutics Company Details

11.1.2 Sarepta Therapeutics Business Overview

11.1.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Introduction

11.1.4 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Business (2021–2026)

11.1.5 Sarepta Therapeutics Recent Development

11.2 PTC Therapeutics

11.2.1 PTC Therapeutics Company Details

11.2.2 PTC Therapeutics Business Overview

11.2.3 PTC Therapeutics Duchenne Muscular Dystrophy Introduction

11.2.4 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy Business (2021–2026)

11.2.5 PTC Therapeutics Recent Development

11.3 Pfizer

11.3.1 Pfizer Company Details

11.3.2 Pfizer Business Overview

11.3.3 Pfizer Duchenne Muscular Dystrophy Introduction

11.3.4 Pfizer Revenue in Duchenne Muscular Dystrophy Business (2021–2026)

11.3.5 Pfizer Recent Development

11.4 Bristol-Myers Squibb

11.4.1 Bristol-Myers Squibb Company Details

11.4.2 Bristol-Myers Squibb Business Overview

11.4.3 Bristol-Myers Squibb Duchenne Muscular Dystrophy Introduction

11.4.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Business (2021–2026)

11.4.5 Bristol-Myers Squibb Recent Development

11.5 Italfarmaco

11.5.1 Italfarmaco Company Details

11.5.2 Italfarmaco Business Overview

11.5.3 Italfarmaco Duchenne Muscular Dystrophy Introduction

11.5.4 Italfarmaco Revenue in Duchenne Muscular Dystrophy Business (2021–2026)

11.5.5 Italfarmaco Recent Development

11.6 Santhera Pharmaceuticals

11.6.1 Santhera Pharmaceuticals Company Details

11.6.2 Santhera Pharmaceuticals Business Overview

11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Introduction

11.6.4 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Business (2021–2026)

11.6.5 Santhera Pharmaceuticals Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

PTC Therapeutics

Sarepta Therapeutics

Pfizer Inc

Bristol–Myers Squibb

Italfarmaco S.p.A.

Santhera Pharmaceuticals

List of Tables

Table 1. Global Duchenne Muscular Dystrophy Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Exondys 51

Table 3. Key Players of Emflaza

Table 4. Key Players of Translarna

Table 5. Global Duchenne Muscular Dystrophy Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 6. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 7. Global Duchenne Muscular Dystrophy Market Size by Region (US$ Million), 2021–2026

Table 8. Global Duchenne Muscular Dystrophy Market Share by Region (2021–2026)

Table 9. Global Duchenne Muscular Dystrophy Forecasted Market Size by Region (US$ Million), 2027–2032

Table 10. Global Duchenne Muscular Dystrophy Market Share by Region (2027–2032)

Table 11. Duchenne Muscular Dystrophy Market Trends

Table 12. Duchenne Muscular Dystrophy Market Drivers

Table 13. Duchenne Muscular Dystrophy Market Challenges

Table 14. Duchenne Muscular Dystrophy Market Restraints

Table 15. Global Duchenne Muscular Dystrophy Revenue by Players (US$ Million), 2021–2026

Table 16. Global Duchenne Muscular Dystrophy Market Share by Players (2021–2026)

Table 17. Global Top Duchenne Muscular Dystrophy Players by Tier (Tier 1, Tier 2, and Tier 3), based on Duchenne Muscular Dystrophy Revenue, 2025

Table 18. Ranking of Global Top Duchenne Muscular Dystrophy Companies by Revenue (US$ Million) in 2025

Table 19. Global 5 Largest Players Market Share by Duchenne Muscular Dystrophy Revenue (CR5 and HHI), 2021–2026

Table 20. Global Key Players of Duchenne Muscular Dystrophy, Headquarters and Area Served

Table 21. Global Key Players of Duchenne Muscular Dystrophy, Products and Applications

Table 22. Global Key Players of Duchenne Muscular Dystrophy, Date of General Availability (GA)

Table 23. Mergers and Acquisitions, Expansion Plans

Table 24. Global Duchenne Muscular Dystrophy Market Size by Type (US$ Million), 2021–2026

Table 25. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2021–2026)

Table 26. Global Duchenne Muscular Dystrophy Forecasted Market Size by Type (US$ Million), 2027–2032

Table 27. Global Duchenne Muscular Dystrophy Revenue Market Share by Type (2027–2032)

Table 28. Global Duchenne Muscular Dystrophy Market Size by Application (US$ Million), 2021–2026

Table 29. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2021–2026)

Table 30. Global Duchenne Muscular Dystrophy Forecasted Market Size by Application (US$ Million), 2027–2032

Table 31. Global Duchenne Muscular Dystrophy Revenue Market Share by Application (2027–2032)

Table 32. North America Duchenne Muscular Dystrophy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 33. North America Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2021–2026

Table 34. North America Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2027–2032

Table 35. Europe Duchenne Muscular Dystrophy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 36. Europe Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2021–2026

Table 37. Europe Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2027–2032

Table 38. Asia-Pacific Duchenne Muscular Dystrophy Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 39. Asia-Pacific Duchenne Muscular Dystrophy Market Size by Region (US$ Million), 2021–2026

Table 40. Asia-Pacific Duchenne Muscular Dystrophy Market Size by Region (US$ Million), 2027–2032

Table 41. Latin America Duchenne Muscular Dystrophy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. Latin America Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2021–2026

Table 43. Latin America Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2027–2032

Table 44. Middle East & Africa Duchenne Muscular Dystrophy Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Middle East & Africa Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2021–2026

Table 46. Middle East & Africa Duchenne Muscular Dystrophy Market Size by Country (US$ Million), 2027–2032

Table 47. Sarepta Therapeutics Company Details

Table 48. Sarepta Therapeutics Business Overview

Table 49. Sarepta Therapeutics Duchenne Muscular Dystrophy Product

Table 50. Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy Business (US$ Million), 2021–2026

Table 51. Sarepta Therapeutics Recent Development

Table 52. PTC Therapeutics Company Details

Table 53. PTC Therapeutics Business Overview

Table 54. PTC Therapeutics Duchenne Muscular Dystrophy Product

Table 55. PTC Therapeutics Revenue in Duchenne Muscular Dystrophy Business (US$ Million), 2021–2026

Table 56. PTC Therapeutics Recent Development

Table 57. Pfizer Company Details

Table 58. Pfizer Business Overview

Table 59. Pfizer Duchenne Muscular Dystrophy Product

Table 60. Pfizer Revenue in Duchenne Muscular Dystrophy Business (US$ Million), 2021–2026

Table 61. Pfizer Recent Development

Table 62. Bristol-Myers Squibb Company Details

Table 63. Bristol-Myers Squibb Business Overview

Table 64. Bristol-Myers Squibb Duchenne Muscular Dystrophy Product

Table 65. Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Business (US$ Million), 2021–2026

Table 66. Bristol-Myers Squibb Recent Development

Table 67. Italfarmaco Company Details

Table 68. Italfarmaco Business Overview

Table 69. Italfarmaco Duchenne Muscular Dystrophy Product

Table 70. Italfarmaco Revenue in Duchenne Muscular Dystrophy Business (US$ Million), 2021–2026

Table 71. Italfarmaco Recent Development

Table 72. Santhera Pharmaceuticals Company Details

Table 73. Santhera Pharmaceuticals Business Overview

Table 74. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Product

Table 75. Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy Business (US$ Million), 2021–2026

Table 76. Santhera Pharmaceuticals Recent Development

Table 77. Research Programs/Design for This Report

Table 78. Key Data Information from Secondary Sources

Table 79. Key Data Information from Primary Sources

Table 80. Authors List of This Report

List of Figures

Figure 1. Duchenne Muscular Dystrophy Picture

Figure 2. Global Duchenne Muscular Dystrophy Market Size Comparison by Type (US$ Million), 2021–2032

Figure 3. Global Duchenne Muscular Dystrophy Market Share by Type: 2025 vs 2032

Figure 4. Exondys 51 Features

Figure 5. Emflaza Features

Figure 6. Translarna Features

Figure 7. Global Duchenne Muscular Dystrophy Market Size by Application (US$ Million), 2021–2032

Figure 8. Global Duchenne Muscular Dystrophy Market Share by Application: 2025 vs 2032

Figure 9. Hospitals Case Studies

Figure 10. Clinics Case Studies

Figure 11. Home Care Case Studies

Figure 12. Duchenne Muscular Dystrophy Report Years Considered

Figure 13. Global Duchenne Muscular Dystrophy Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 14. Global Duchenne Muscular Dystrophy Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 15. Global Duchenne Muscular Dystrophy Market Share by Region: 2025 vs 2032

Figure 16. Global Duchenne Muscular Dystrophy Market Share by Players in 2025

Figure 17. Global Duchenne Muscular Dystrophy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 18. The Top 10 and 5 Players Market Share by Duchenne Muscular Dystrophy Revenue in 2025

Figure 19. North America Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 20. North America Duchenne Muscular Dystrophy Market Share by Country (2021–2032)

Figure 21. United States Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 22. Canada Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 23. Europe Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 24. Europe Duchenne Muscular Dystrophy Market Share by Country (2021–2032)

Figure 25. Germany Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 26. France Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 27. U.K. Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 28. Italy Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 29. Russia Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 30. Ireland Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. Asia-Pacific Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 32. Asia-Pacific Duchenne Muscular Dystrophy Market Share by Region (2021–2032)

Figure 33. China Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Japan Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. South Korea Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 36. Southeast Asia Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. India Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. Australia & New Zealand Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Latin America Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Latin America Duchenne Muscular Dystrophy Market Share by Country (2021–2032)

Figure 41. Mexico Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Brazil Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Middle East & Africa Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 44. Middle East & Africa Duchenne Muscular Dystrophy Market Share by Country (2021–2032)

Figure 45. Israel Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. Saudi Arabia Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. UAE Duchenne Muscular Dystrophy Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. Sarepta Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Business (2021–2026)

Figure 49. PTC Therapeutics Revenue Growth Rate in Duchenne Muscular Dystrophy Business (2021–2026)

Figure 50. Pfizer Revenue Growth Rate in Duchenne Muscular Dystrophy Business (2021–2026)

Figure 51. Bristol-Myers Squibb Revenue Growth Rate in Duchenne Muscular Dystrophy Business (2021–2026)

Figure 52. Italfarmaco Revenue Growth Rate in Duchenne Muscular Dystrophy Business (2021–2026)

Figure 53. Santhera Pharmaceuticals Revenue Growth Rate in Duchenne Muscular Dystrophy Business (2021–2026)

Figure 54. Bottom-up and Top-down Approaches for This Report

Figure 55. Data Triangulation

Figure 56. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Drugs for Duchenne Muscular Dystrophy DMD Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myotonic Dystrophy Drug Market Research Report 2024

Myotonic Dystrophy Medication Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myotonic Dystrophy Treatment Market Research Report 2025

Myotonic Dystrophy Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Spinal Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Duchenne Muscular Dystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Myasthenia Gravis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Myasthenia Gravis Therapies Market Research Report 2024

Global Spinal Muscular Atrophy SMA Treatment Market Research Report 2024

Global Becker Muscular Dystropy Market Research Report 2025

Global Sarcopenia Treatments Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030

Adrenoleukodystrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Sarcopenia Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Myotonic Muscular Dystrophy DMD Treatments Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Dystrophin Market Research Report 2024

Global Ophthalmology Disorders Drug Market Insights Forecast to 2030

Spinal Muscular Atrophy SMA Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Spinal and Bulbar Muscular Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions